In the News

PULMONX ANNOUNCES THAT ONE OF THE LEADING HEALTH CARE PROVIDERS IN THE UNITED STATES NOW COVERS THE ZEPHYR VALVE FOR BRONCHSCOPIC LUNG VOLUME REDUCTION IN PATIENTS WITH SEVERE EMPHYSEMA

The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.

Read More


FDA APPROVES ZEPHYR ENDOBRONCHIAL VALVE FOR TREATING SEVERE EMPHYSEMA

The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.

Read More


ZEPHYR ENDOBRONCHIAL VALVES IMPROVE BREATHING, QUALITY OF LIFE AND ACTIVITY FOR SEVERE EMPHYSEMA PATIENTS IN US PIVOTAL TRIAL

Pulmonx®Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD).

Read More